Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity

Table 1

Baseline characteristics of normal BMI patients with T2DM and visceral adiposity.

	Pre-exenatide therapy ()	Pre-humalog Mix25 therapy ()	value
Sex, female (%)	18 (36.73)	23 (50.00)	0.19
Age (years)			0.06
Weight (kg)			0.02
WC (cm)			0.65
BMI (kg/m^2)			0.07
SBP (mmHg)			0.03
DBP (mmHg)			0.28
Disease course (years)	8.00 (4.50-14.50)	11.00 (7.00-14.00)	0.08
FPG (mmol/L)			0.98
2hPBG (mmol/L)			0.22
FINS (mIU/L)			0.33
HbA1c (%)			0.74
TC (mmol/L)			0.88
TG (mmol/L)			0.99
AST (IU/L)			0.89
ALT (IU/L)			0.50
Creatinine (μmol/L)			0.22
FGF-21 (pg/mL)			0.10
SAT (cm^2)			0.48
VAT (cm^2)			0.95
LFC (%)			0.41
Smoking, (%)	19 (39.78)	13 (28.26)	0.19
Drinking, (%)	22 (44.90)	24 (52.17)	0.31
Diabetic chronic complications, (%)	2 (4.10)	3 (6.52)	0.47
Sulfonylureas, (%)	18 (36.73)	17 (36.95)	0.58
Biguanides, (%)	27 (55.10)	17 (36.96)	0.06
Glinides, (%)	4 (8.16)	4 (8.69)	0.61
Glucosidase inhibitors, (%)	7 (14.29)	10 (21.74)	0.25

ALT: glutamic pyruvic transaminase; AST: glutamic oxalacetic transaminase; BMI: body mass index; DBP: diastolic blood pressure; FGF-21: fibroblast growth factor 21; FINS: fasting insulin; FPG: fasting plasma glucose; HbA1c: glycated haemoglobin; LFC: liver fat content; SAT: subcutaneous and visceral adipose tissue; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides; VAT: visceral adipose tissue; WC: waist circumference; 2hFBG: 2 h plasma blood glucose. Data are expressed as the deviation or median (interquartile range).